A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004600/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
本研究双盲阶段的主要目标，是评估三种固定剂量的帕利哌酮缓释剂（paliperidone ER，3mg/日、9mg/日与15mg/日）相较于安慰剂，对成人精神分裂症患者的疗效与安全性
提供机构：
Vivli
创建时间：
2019-09-19
